Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Naruhiko MIZUTA"'
Autor:
Mari Soushi, Tetsuya Taguchi, Kei Yamada, Mariko Goto, Seiichi Imanishi, Akiko Okamoto, Asako Hamaoka, Tatsuya Kotani, Akio Yanagisawa, Takayuki Matsuda, Eiichi Konishi, Sadao Kawakami, Kenichirou Fukuda, Kouichi Sakaguchi, Katsuhiko Nakatsukasa, Yoshifumi Fujita, Midori Morita, Hiroshi Koyama, Yayoi Kadotani, Aya Imai, Yoshimi Oouchi, Ikuya Fujiwara, Naruhiko Mizuta
Publikováno v:
Breast Cancer. 24:92-97
The standard primary systemic therapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancer is anthracyclines and/or taxanes combined with trastuzumab, which demonstrates a high pathological complete response (pCR). A pCR is a p
Autor:
Naruhiko Mizuta, Miho Ichida, Hiroo Nakajima, Junji Magae, Ikuya Fujiwara, Asako Nishiyama, Mahiro Ohashi, Yoshimi Umeda, Koichi Sakaguchi
Publikováno v:
World Journal of Surgery. 34:2197-2203
Skin-sparing partial mastectomy (SSPM) has yet to be investigated as a breast-conserving therapy for early-stage breast cancer. We report the clinical outcomes for video-assisted SSPM (VA-SSPM) with immediate breast reconstruction using autogenous ti
Autor:
Junji Magae, Hiroo Nakajima, Yasushi Hachimine, Koichi Sakaguchi, Ikuya Fujiwara, Naruhiko Mizuta
Publikováno v:
Annals of Surgical Oncology. 16:1982-1989
This study analyzed clinical results of video-assisted breast-conserving surgery for breast cancer.Video-assisted breast-conserving surgery is indicated for breast cancer that has not invaded the skin. A skin incision is made at an inconspicuous site
Publikováno v:
Annals of Surgery. 249:91-96
Objective: To analyze therapeutic results of video-assisted breast-conserving surgery (VA-BCS) for early stage breast cancer. Background: VA-BCS for breast cancer has been developed in Japan, and is indicated for breast cancer unaccompanied by skin i
Autor:
Hiroo NAKAJIMA, Ikuya FUJIWARA, Koichi SAKAGUCHI, Naruhiko MIZUTA, Yasushi HACHIMINE, Katsuhiko NAKATSUKASA, Miho ICHIDA
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 33:1-7
Autor:
Hiroo Nakajima, Koichi Sakaguchi, Ikuya Fujiwara, Naruhiko Mizuta, Yasushi Hachimine, Katsuhiko Nakatsukasa, Aya Masaki
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 17:154-160
Autor:
Miho Ichida, Naruhiko Mizuta, Koichi Sakaguchi, Akio Yanagisawa, Ikuya Fujiwara, Yasushi Hachimine, Eiichi Konishi, Mahiro Ohashi, Hiroo Nakajima, Katsuhiko Nakatsukasa
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69:1866-1871
Autor:
Naruhiko Mizuta, Satoshi Takahashi, Atsushi Yoshimori, Ryoko Takasawa, Hiroo Nakajima, Koichi Sakaguchi, Ikuya Fujiwara, Sei-ichi Tanuma
Publikováno v:
Breast Cancer. 15:65-72
An antagonistic peptide called HRAP that binds to the human HER2 molecule was designed by our computational method. In silico docking study demonstrated the specific interaction of HRAP with the dimerization domain in the HER2 molecule. Interestingly
Autor:
Junji Magae, Ikuya Fujiwara, Chiharu Furukawa, Young-Chae Chang, Naruhiko Mizuta, Mitsuhiko Mizuta, Hiroo Nakajima, Koichi Sakaguchi
Publikováno v:
The Journal of Antibiotics. 60:682-689
Estrogen receptor-negative breast cancers generally are highly malignant, resistant to chemotherapy and poorly prognostic. Here we demonstrate that estrogen receptor-negative human breast cancer cell lines highly express Fra-1, c-Fos and c-Jun, compo
Autor:
Kiyoshi Sawai, Junji Magae, Mitsuhiko Mizuta, Naruhiko Mizuta, Hisakazu Yamagishi, Hiroo Nakajima, Mie Tsuruga, Ikuya Fujiwara, Koichi Sakaguchi
Publikováno v:
Cancer Letters. 253:89-96
YM529, a new third generation bisphosphonate, induced apoptosis of a human breast cancer cell line, MX-1. Cytotoxic activity of YM529 was more potent than that of incadronate. YM529 activated caspase-9, but not caspase-8, and induced the release of c